Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$4.28 USD

4.28
2,997,562

+0.19 (4.65%)

Updated Apr 29, 2024 03:55 PM ET

After-Market: $4.28 0.00 (0.00%) 4:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sanghamitra Saha headshot

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

Why Is Novavax (NVAX) Down 14.7% Since Last Earnings Report?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View

Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of May 8, 2023

A Biotech Company Developing Vaccines and a Restaurant Stock with Earnings Growth.

Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of -0.89% and 40.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More

Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.

Novavax (NVAX) Gains As Market Dips: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $7.15, marking a +1.56% move from the previous day.

Amgen (AMGN) Q1 Earnings Beat Estimates

Amgen (AMGN) delivered earnings and revenue surprises of 3.65% and 0.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

Novavax (NVAX) closed the most recent trading day at $7.53, moving -1.31% from the previous trading session.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $6.59, marking a -1.05% move from the previous day.

Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $5.76, marking a -0.35% move from the previous day.

Novavax (NVAX) Gains But Lags Market: What You Should Know

Novavax (NVAX) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day.

Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down

Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.

Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of -147.83% and 5.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More

Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.

Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

Novavax (NVAX) closed at $9.07 in the latest trading session, marking a -0.33% move from the prior day.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

Novavax (NVAX) closed the most recent trading day at $9.99, moving -1.96% from the previous trading session.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $9.88, marking a +1.02% move from the previous day.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

Omega Therapeutics, Inc. (OMGA) Surges 37.2%: Is This an Indication of Further Gains?

Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.